ALSTON & BIRD LLP for TRAVERE THERAPEUTICS
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 21, 2025 | $60,000 | Replaced |
| 1st Quarter - Amendment (this page) | Mar 3, 2026 | $60,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ZOE ATCHINSON | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Medicare/Medicaid MMM
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation impacting products approved under the Accelerated Approval pathway. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ZOE ATCHINSON | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Pharmacy PHA
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding orphan drug pricing, value, and reimbursement, relative to the Inflation Reduction Act of 2022 (Pub. L. No. 117-169, 136 Stat. 1818 (2022)). Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ZOE ATCHINSON | — |
| MARK RAYDER | — |
Medical/Disease Research/Clinical Labs MED
Legislation regarding clinical research for rare diseases and orphan drug development, and the Accelerated Approval pathway. Support of reauthorization of priority review voucher program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ZOE ATCHINSON | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
| ROBERT SIGGINS | — |
Taxation/Internal Revenue Code TAX
H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit. Legislation to improve education and care pathways for patients with rare kidney disease.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
| ROBERT SIGGINS | — |
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.